Wollert Kai C, Kempf Tibor, Peter Timo, Olofsson Sylvia, James Stefan, Johnston Nina, Lindahl Bertil, Horn-Wichmann Rüdiger, Brabant Georg, Simoons Maarten L, Armstrong Paul W, Califf Robert M, Drexler Helmut, Wallentin Lars
Department of Cardiology and Angiology, Hannover Medical School, Germany.
Circulation. 2007 Feb 27;115(8):962-71. doi: 10.1161/CIRCULATIONAHA.106.650846. Epub 2007 Feb 5.
Growth-differentiation factor-15 (GDF-15) is a member of the transforming growth factor-beta cytokine superfamily that is induced in the heart after ischemia-and-reperfusion injury. Circulating levels of GDF-15 may provide prognostic information in patients with non-ST-elevation acute coronary syndrome.
Blood samples were obtained on admission from 2081 patients with acute chest pain and either ST-segment depression or troponin elevation who were included in the Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV Non-ST-Elevation Acute Coronary Syndrome trial and from a matching cohort of 429 apparently healthy individuals. GDF-15 levels were determined by immunoradiometric assay. Approximately two thirds of patients presented with GDF-15 levels above the upper limit of normal in healthy controls (1200 ng/L); one third presented with levels >1800 ng/L. Increasing tertiles of GDF-15 were associated with an enhanced risk of death at 1 year (1.5%, 5.0%, and 14.1%; P<0.001). By multiple Cox regression analysis, only the levels of GDF-15 and N-terminal pro-B-type natriuretic peptide, together with age and a history of previous myocardial infarction, contributed independently to 1-year mortality risk. Receiver operating characteristic curve analyses further illustrated that GDF-15 is a strong marker of 1-year mortality risk (area under the curve, 0.757; best cutoff, 1808 ng/L). At this cutoff value, GDF-15 added significant prognostic information in patient subgroups defined by age; gender; time from symptom onset to admission; cardiovascular risk factors; previous cardiovascular disease; and the risk markers ST-segment depression, troponin T, N-terminal pro-B-type natriuretic peptide, C-reactive protein, and creatinine clearance.
GDF-15 is a new biomarker of the risk for death in patients with non-ST-elevation acute coronary syndrome that provides prognostic information beyond that provided by established clinical and biochemical markers.
生长分化因子15(GDF - 15)是转化生长因子-β细胞因子超家族的成员,在心肌缺血再灌注损伤后在心脏中被诱导产生。GDF - 15的循环水平可能为非ST段抬高急性冠状动脉综合征患者提供预后信息。
从全球开放闭塞动脉策略(GUSTO)-IV非ST段抬高急性冠状动脉综合征试验中纳入的2081例急性胸痛且伴有ST段压低或肌钙蛋白升高的患者以及429名明显健康个体的匹配队列中,在入院时采集血样。通过免疫放射分析测定GDF - 15水平。约三分之二的患者GDF - 15水平高于健康对照的正常上限(1200 ng/L);三分之一的患者水平>1800 ng/L。GDF - 15三分位数增加与1年时死亡风险增加相关(1.5%、5.0%和14.1%;P<0.001)。通过多因素Cox回归分析,只有GDF - 15和N末端B型脑钠肽前体水平,以及年龄和既往心肌梗死病史,独立影响1年死亡风险。受试者工作特征曲线分析进一步表明,GDF - 15是1年死亡风险的有力标志物(曲线下面积,0.757;最佳截断值,1808 ng/L)。在此截断值时,GDF - 15在按年龄、性别、症状发作至入院时间、心血管危险因素、既往心血管疾病以及风险标志物ST段压低、肌钙蛋白T、N末端B型脑钠肽前体、C反应蛋白和肌酐清除率定义的患者亚组中增加了显著的预后信息。
GDF -